Cresanto Global Ltd. lags significantly behind its peers in key financial metrics, reflecting its weak market position and operational challenges. The analysis reveals that while some peers demonstrate strong profitability and growth, Cresanto's performance metrics indicate financial distress, making it an unappealing investment option at this time.

• • Cresanto has no revenue growth, EPS, or profitability metrics, indicating severe operational issues.
• • Sun Pharmaceutical leads in profitability metrics with high ROE and EPS growth.
• • Cresanto has the lowest valuation metrics, including a negative PE and PBV, indicating it's not a viable value pick.